Urinary Incontinence, Stress

Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trialSAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation therapy was evaluated in the independent, investigator-initiated WATER III trial. This study compared Aquablation therapy to laser enucleation for treating large prostates, with results presented in the prestigious Game-Changer session at the European Association of Urology (EAU) 2025 Annual Congress in Madrid, Spain. WATER III is an international, prospective, multicenter study comparing Aquablation therapy to laser enucleation in prostate sizes 80-180mL. The study treated 186 men between December 2020 and September 2024 and reported three-month primary safety and efficacy endpoints and will subsequently follow patients to five years. The three-month results demonstrated that Aquablation therapy delivered substantially similar symptom relief while showing significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Additionally, the procedural transfusion rate in the Aquablation therapy arm was 0%. These findings demonstrate that modern Aquablation therapy techniques are both safe and highly reproducible in managing bleeding risk. "WATER III represents a significant milestone in our mission to establish Aquablation therapy as the standard of care for patients suffering with BPH," said Reza Zadno, CEO of PROCEPT BioRobotics. "Building on our previous randomized WATER data comparing Aquablation therapy to TURP, WATER III demonstrates that Aquablation therapy delivers compelling clinical outcomes compared to laser enucleation. What makes these results particularly meaningful is Aquablation therapy's ability to deliver effective symptom relief while preserving critical quality of life factors—specifically sexual function and continence. These findings reinforce our dedication to providing treatments that address the complete patient experience." “The WATER III results are impressive, demonstrating that Aquablation therapy can achieve outcomes comparable to laser enucleation.” said Dr. Naeem Bhojani, University of Montreal. “The consistent efficacy coupled with the significantly lower rates of ejaculatory dysfunction and stress incontinence represents a meaningful advancement for patients seeking treatment for BPH. The effectiveness of Aquablation therapy is shown by its ability to achieve similar results as highly skilled and experienced laser enucleation surgeons.” These results add to Aquablation therapy’s robust clinical foundation, which include the randomized WATER study (Aquablation therapy vs. TURP in 30-80 mL prostates) with five-year results, WATER II (Aquablation therapy in large prostates 80-150 mL) with five-year results, coupled with over 150 peer-reviewed publications. The growing body of clinical evidence, including multiple randomized clinical studies, demonstrate Aquablation therapy is a globally, reproducible procedure with the potential to become the BPH standard of care for all prostate sizes. About Aquablation TherapyAquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements. Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/ Media Contact:Laurie VertuccioDirector of Marketing(781) 888-0439l.vertuccio@procept-biorobotics.com Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

BASEL, Switzerland, March 20, 2025 /PRNewswire/ -- Versameb AG ("Versameb"), a clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the issuance of the Notice of Allowance of first Composition of Matter patent in China for its innovative signal peptide technology. This achievement represents a significant milestone in Versameb's mission to advance RNA-based therapeutics and expand its intellectual property portfolio globally. The newly allowed patent application encompasses the proprietary technology of using signal peptides to enhance the delivery and expression of heterologous proteins, which can be applied across various therapeutic areas. This breakthrough technology is part of Versameb's VERSagile platform, designed to optimize the potency and efficacy of RNA therapeutics. Notably, this technology is used in Versameb's lead compound VMB-100, currently under development for the treatment of stress urinary incontinence (SUI). "We are thrilled to receive this patent in China, which highlights the innovative nature of our technology and strengthens our position in the rapidly evolving field of RNA therapeutics," said Klaas Zuideveld, Chief Executive Officer of Versameb AG. "This patent is a testament to our team's dedication and expertise in developing cutting-edge solutions to address unmet medical needs. We look forward to leveraging this technology to advance our pipeline and bring new therapies to patients worldwide." The granting of this patent in China marks a significant step forward for Versameb as it continues to expand its global footprint and protect its innovative technologies. The company remains committed to advancing its research and development efforts to bring transformative RNA-based therapies to market. About VMB-100 VMB-100 is an intramuscular mRNA treatment encoding human IGF-1, aimed at treating stress urinary incontinence (SUI). It shows promise for sustained muscle regeneration after short-term use. Preclinical studies revealed that VMB-100 boosts IGF-1 expression in human muscle cells and accelerates urinary sphincter muscle regeneration in animal SUI models. The FDA recently cleared the IND application for VMB-100, and Versameb is currently planning a Phase 2a dose-ascending study for moderate SUI in women, scheduled for 2025. About Stress Urinary Incontinence Stress urinary incontinence is a common condition among women, characterized by the involuntary leakage of urine during physical activities due to a weakened urinary sphincter muscle. SUI is the most common form of urinary incontinence, affecting 86% of incontinent women. Overall, it is estimated that more than 30% of adult women worldwide suffer from SUI. Despite its widespread prevalence, there are currently no approved pharmacological therapies for SUI available in the United States. Current standard of care protocol includes short-term solutions like pelvic floor therapy or a highly invasive surgical procedure in which a sling is permanently implanted into the urethra or bladder neck. About Versameb AG Versameb AG is a privately held biotechnology company focused on discovering and developing innovative RNA-based therapeutics. Founded in Basel in 2018, Versameb is led by a team of experienced scientists and leaders with proven expertise in drug discovery and development, from lab bench to patient. Versameb's proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. This unique technology enables the modulation of protein expression and allows for the simultaneous interaction with multiple therapeutic targets within a single molecular construct, as well as precise cellular targeting. The pipeline includes lead candidate programs in urology, solid tumors and rare diseases. Versameb aims to complete its first in-human proof-of-concept clinical study and is committed to advancing its platform. For more information about Versameb, please visit the website at and follow on LinkedIn. SOURCE Versameb AG WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WEDNESDAY, Feb. 26, 2025 -- Eating behavior and consuming certain foods are associated with perceived pelvic floor disorders, according to a study recently published in Women's Health . Mari A. Kuutti, from the University of Jyväskylä in Finland, and colleagues conducted a cross-sectional, observational study involving 1,098 Finnish women aged 47 to 55 years to examine the associations of eating behavior with symptoms of pelvic floor disorders. The researchers found that middle-aged women with disordered eating style were more likely to experience the symptoms of stress urinary incontinence and constipation or defecation difficulties (odds ratios, 1.5 and 1.4, respectively) in adjusted models. The associations were abolished by the addition of body mass index to the models. Regardless of eating style, more frequent consumption of ready-made, highly processed foods and fast foods was independently associated with symptoms of stress urinary incontinence (odds ratios, 1.5 and 1.5); consumption of ready-made foods was associated with urgency urinary incontinence symptoms (odds ratio, 1.4). There was an independent association seen for daily consumption of fruits with symptoms of stress urinary incontinence (odds ratio, 0.8). Independent of eating style, daily consumption of porridge was associated with symptoms of constipation or defecation difficulties (odds ratio, 1.7). There was an inverse association for alcohol consumption with constipation and defecation difficulties (odds ratio, 0.9). Lower odds for stress urinary incontinence were seen for women with overall higher-quality diets. "Since we found the disordered eating style and some dietary items to be associated with perceived pelvic floor disorders, our study justifies further studies with longitudinal designs to investigate causality," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.